Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | TSHR | P16473 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241724 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL3217829 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL13241723 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL3217836 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL1405467 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL1405466 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL3217840 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL3184563 | 0.78 | ALDH1A1 (0.65) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL134659 | 0.77 | ALDH1A1 (0.56) | ALDH1A1TSHRMAPK1HSD17B10TP53 | |
| SCHEMBL65261 | 0.76 | ALDH1A1 (1.00) | ALDH1A1TSHRMAPK1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104927053-B | Polyimide precursor composition, the method for preparing polyimides formed body and polyimides formed body | 富士施乐株式会社 | 2018-07-13 | — | — | CN | disclosed |
| WO-2016149432-A1 | METHOD OF COLORING HAIR WITH DIRECT DYE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | ALDH1A1 1890/4885TSHR 2713/4885MAPK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.